Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]PBR-28
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[11C]PBR-28 is a second-generation radioligand used in positron emission tomography (PET) imaging to measure the 18 kDa translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor. TSPO is expressed on activated microglia, endothelial cells, and immune cells. The primary use of [11C]PBR-28 is as a biomarker for neuroinflammation and microglial activation in various neurological diseases such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease. Its binding affinity to TSPO can be affected by genetic polymorphisms (notably rs6971), which stratify individuals into low-, mixed-, or high-affinity binders. Compared to first-generation tracers like [^11C]-PK11195, [11C]PBR-28 offers improved signal-to-noise characteristics for brain imaging[3][4][5][6].
- Other names
- (methyl-(11)C)N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine
02
Targets
TSPO (Translocator Protein (18 kDa))
Beyond the preview
Go deeper on [11C]PBR-28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]PBR-28.